Her2-Targeted Therapies in Non–Small Cell Lung Cancer

Abstract excerpt

Sensitivity to Her2-directed therapies is complex and involves expression not only of Her2 but also of other epidermal growth factor receptor (EGFR) family members, their ligands, and molecules that influence pathway activity, such as insulin-like growth factor-1 receptor, PTEN, and p27. The EGFR experience has taught us that responses can easily be diluted in an unselected cohort of patients. To date, trials of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chronic Lymphocytic Leukemia Research
• Share to HER2/EGFR in Cancer Research
• Share to Lung Cancer Treatments and Mutations